Effect of Cerebral Microbleeds on Cognitive Function and Quality of Life in Parkinson Disease

16 March 2022: Clinical Research

Qixiong Qin ^1ABCDEF , Hengming Wan ^2C , Danlei Wang ^1B , Jingyi Li ^1B , Qingmei Yang ^1B , Jingwei Zhao ^1B , Zheng Xue ^1ADFG

DOI: 10.12659/MSM.935026

Med Sci Monit 2022; 28:e935026

Table 4 The associations of cerebral microbleeds (CMBs) with cognition and quality of life in Parkinson disease.

	The presence of CMBs
	R2	β	p-value

MMSE total score	0.140	0.301
MoCA total score	0.104	0.289
Visuospatial abilities	0.139	−0.165	0.027
Naming	0.098	−0.197	0.010
Attention	0.173	−0.298
Language	0.040	0.037	0.629
Abstraction	0.053	−0.003	0.971
Delayed memory	0.099	−0.128	0.094
Orientation	0.080	−0.151	0.050

PDQ-39 SI	0.113	0.108	0.166
Mobility SI	0.114	0.103	0.188
Activity of daily living SI	0.078	0.112	0.159
Emotional well-beings SI	0.033	0.024	0.765
Stigma SI	0.007	0.033	0.684
Social support SI	0.020	−0.065	0.426
Cognition SI	0.093	0.074	0.346
Communication SI	0.082	0.022	0.785
Bodily discomfort SI	0.066	−0.045	0.568
Adjusted values are listed in the table. The association of CMBs with MMSE and MoCA was adjusted for sex, age, education levels, disease duration, and LEDD. The association of CMBs with QoL was adjusted for sex, age, education levels, disease duration, LEDD, UPDRS-III, and MMSE or MoCA. ^# Compared with CMB-free group, the difference was statistically significant. CMBs – cerebral microbleeds; MMSE – Mini Mental State Examination; MoCA – Montreal Cognitive Assessment; QoL – quality of life; PDQ-39 – 39-item Parkinson disease questionnaire; SI – summary index.